COL1A1 and osteogenesis imperfecta: This approach may be applicable for diseases such as osteogenesis imperfecta (OI), where OTIs show promise in correcting pathogenic point mutations in collagen genes like COL1A1 while avoiding off-target edits in wild-type alleles [20].